High FGFR4 expression and tumor-infiltrating Tregs synergistically predict enhanced therapeutic response to lenvatinib plus anti-PD-1 combination therapy in HCC, positioning these biomarkers for clinical stratification of patients likely to benefit from this regimen (21). Here, FGFR4 is linked to hepatocellular carcinoma.